OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Computing brain metastasis impact	705
Digging for treasures in the tumour interactome	679
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	483
Combinatorial strategies to target RAS-driven cancers	475
Claudin proteins as emerging therapeutic targets for solid tumours	462
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	418
Emerging strategies to investigate the biology of early cancer	375
Exploiting metabolic cell death for cancer therapy	368
Oncofetal reprogramming in tumour development and progression	302
INVADEseq to study the intratumoural microbiota at host single-cell resolution	295
Fructose takes a detour to feed cancer	292
Implementing practice-changing progress for managing cancer of unknown primary	290
Mapping the prostate cell family tree	276
Fighting cancer with fat	271
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	262
The evolution of cancer and ageing: a history of constraint	260
Tertiary lymphoid structures as hubs of antitumour immunity	255
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	252
Connie J. Eaves (1944–2024)	250
The recruitment of metastasis-associated monocytes	248
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	223
How medical anthropology can contribute to cancer research	220
Translating premalignant biology to accelerate non-small-cell lung cancer interception	214
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	212
Avoiding cancer through collective behaviour	209

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	199
Epithelial and stromal co-evolution and complicity in pancreatic cancer	194
Nanoreceptors take down mutant p53	192
Impersonating neurons	188
Tumour EVPs disrupt liver function	187
AACR 2025	185
Measuring HLA disruption using MHC Hammer	183
Gut microbes produce novel genotoxic metabolites	182
Persistence is key	174
Thelpers? More like Ttroublemakers	171
Defining a ‘cells to society’ research framework for appendiceal tumours	166
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	164
No mutation, tumour initiation	164
3D bioprinted cancer models: from basic biology to drug development	160
Rethinking ovarian cancer III: the past decade and future directions	157
Dendritic cells rise and shine	153
Removing barriers to address sex differences in anticancer drug toxicity	151
How chemokines organize the tumour microenvironment	148
Natural killer cells in antitumour adoptive cell immunotherapy	148
Bone voyage: immune crosstalk sets sail	139
B-ring sterols to the rescue	139
Visualizing intratumoural heterogeneity with EpicMIBI	128
Double trouble for the tumour glycocode	127
Identifying spatial cellular structures with SPACE-GM	126
In-depth organoid profiling of pancreatic cancer	123
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	120
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities	118
Context-dependent synthetic lethality — an emerging precision therapeutic approach	115
Opportunities and challenges of targeting cGAS–STING in cancer	113
Linking cell mechanical memory and cancer metastasis	109
The path to leptomeningeal metastasis	108
The immune microenvironment of colorectal cancer	104
Dynamics and specificities of T cells in cancer immunotherapy	101
Regulatory T cells in the tumour microenvironment	98
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	98
Leveraging the replication stress response to optimize cancer therapy	95
Understanding and addressing race disparities in childhood cancer outcomes	94
Race influences the tumour microbiome	94
Encoding spatial tumour dynamics with Starfysh	94
Deciphering the cancer genome and epigenome	91
Cancer nanomedicine	91
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research	83
The link between vitamin D and prostate cancer	81
RNA splicing dysregulation and the hallmarks of cancer	76
ER stress sparks nerve pain	73
Being in the zone	69
Polygenic scores in cancer	68
Re-routing IgE for cancer therapy	68
Acetyl-CoA metabolism in cancer	66
Targeted protein degradation for cancer therapy	66

Z-nucleic acids give immunotherapy a boost	65
Local CAR manufacturing	64
Tamoxifen takes the wheel	62
Integrative medicine in oncology: redefining the standard of care	61
Prime editing GEMMs to model cancer mutations	61
Right ON target: a new RAS-GTP inhibitor	61
When the time is right	60
NOTUM-mediated stem cell competition in CRC	59
Tertiary lymphoid structures in anticancer immunity	59
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	59
Chromothripsis in cancer	59
Decoding cancer across scales with metabolomics	59
Expanding the utility of precision oncology knowledge bases	59
Defining precancer: a grand challenge for the cancer community	52
In vivo labelling system to study cell neighbourhoods	52
Revealing genomic secrets of archival FFPE samples	51
New pathogen on the block	50
Judith Campisi (1948–2024)	50
Melanomagenesis antagonizes stem cell ageing	49
N6-Methyladenosine: an RNA modification as a central regulator of cancer	49
Inferring cancer metabolism from gene-expression data	49
Cancer risk in children with congenital anomalies	48
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	46
The present and future of the Cancer Dependency Map	46
Recent advances in therapeutic cancer vaccines	45
Carcinogenesis at single-cell resolution	44
Patient-derived organoids unveil sarcoma vulnerabilities	39
Transfer RNAs as dynamic and critical regulators of cancer progression	38
Focusing on the complex and dynamic interplay between ageing and cancer	38
Global post-mortem tissue donation programmes to accelerate cancer research	38
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy	37
Epigenomic heterogeneity as a source of tumour evolution	36
Developing dietary interventions as therapy for cancer	36
Traject3d for studying 3D cellular heterogeneity	36
A timeline of tumour-associated macrophage biology	36
Digitally enhanced Raman spectroscopy	35
Harnessing the influenza virus to fight cancer	33
Author Correction: Integrative medicine in oncology: redefining the standard of care	33
We cannot ignore the cancer risks of wildfires	31
Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer	31